Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Fundamental Analysis

NASDAQ:LFCR - US5147661046 - Common Stock

7.59 USD
-0.01 (-0.13%)
Last: 8/25/2025, 4:30:02 PM
7.59 USD
0 (0%)
After Hours: 8/25/2025, 4:30:02 PM
Fundamental Rating

2

Overall LFCR gets a fundamental rating of 2 out of 10. We evaluated LFCR against 54 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of LFCR have multiple concerns. LFCR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LFCR had negative earnings in the past year.
In the past year LFCR had a positive cash flow from operations.
LFCR had negative earnings in 4 of the past 5 years.
LFCR had negative operating cash flow in 4 of the past 5 years.
LFCR Yearly Net Income VS EBIT VS OCF VS FCFLFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

LFCR has a Return On Assets of -20.78%. This is in the lower half of the industry: LFCR underperforms 64.81% of its industry peers.
With a Return On Equity value of -104.15%, LFCR is not doing good in the industry: 79.63% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -20.78%
ROE -104.15%
ROIC N/A
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
LFCR Yearly ROA, ROE, ROICLFCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

LFCR's Profit Margin has improved in the last couple of years.
The Gross Margin of LFCR (33.45%) is worse than 64.81% of its industry peers.
LFCR's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for LFCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
LFCR Yearly Profit, Operating, Gross MarginsLFCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

More info and screens

2

2. Health

2.1 Basic Checks

LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for LFCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LFCR Yearly Shares OutstandingLFCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LFCR Yearly Total Debt VS Total AssetsLFCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.38, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
LFCR's Altman-Z score of 0.38 is on the low side compared to the rest of the industry. LFCR is outperformed by 70.37% of its industry peers.
A Debt/Equity ratio of 2.61 is on the high side and indicates that LFCR has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.61, LFCR is doing worse than 88.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACCN/A
WACC9.49%
LFCR Yearly LT Debt VS Equity VS FCFLFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

LFCR has a Current Ratio of 2.71. This indicates that LFCR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.71, LFCR is in line with its industry, outperforming 50.00% of the companies in the same industry.
LFCR has a Quick Ratio of 1.59. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of LFCR (1.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 1.59
LFCR Yearly Current Assets VS Current LiabilitesLFCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.81%

3.2 Future

The Earnings Per Share is expected to grow by 23.41% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.24% on average over the next years. This is a very strong growth
EPS Next Y41.77%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year3.58%
Revenue Next 2Y7.72%
Revenue Next 3Y11.74%
Revenue Next 5Y21.24%

3.3 Evolution

LFCR Yearly Revenue VS EstimatesLFCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
LFCR Yearly EPS VS EstimatesLFCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LFCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFCR Price Earnings VS Forward Price EarningsLFCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LFCR Per share dataLFCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as LFCR's earnings are expected to grow with 23.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.63%
EPS Next 3Y23.41%

More info and screens

0

5. Dividend

5.1 Amount

LFCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (8/25/2025, 4:30:02 PM)

After market: 7.59 0 (0%)

7.59

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)10-02 2025-10-02
Inst Owners72.41%
Inst Owner ChangeN/A
Ins Owners2.05%
Ins Owner Change11.27%
Market Cap281.06M
Analysts82.22
Price Target10.2 (34.39%)
Short Float %6.91%
Short Ratio15.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.85%
Min EPS beat(2)-207.19%
Max EPS beat(2)15.48%
EPS beat(4)1
Avg EPS beat(4)-58.48%
Min EPS beat(4)-207.19%
Max EPS beat(4)15.48%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.52%
Min Revenue beat(2)3.72%
Max Revenue beat(2)7.32%
Revenue beat(4)4
Avg Revenue beat(4)5.39%
Min Revenue beat(4)3.72%
Max Revenue beat(4)7.32%
Revenue beat(8)5
Avg Revenue beat(8)2.97%
Revenue beat(12)6
Avg Revenue beat(12)-5.27%
Revenue beat(16)6
Avg Revenue beat(16)-18.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.16
P/FCF N/A
P/OCF 91.05
P/B 5.93
P/tB 9.58
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)0.08
OCFY1.1%
SpS3.52
BVpS1.28
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.78%
ROE -104.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.45%
FCFM N/A
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.83%
Cap/Sales 10.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 1.59
Altman-Z 0.38
F-Score5
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)173.77%
Cap/Depr(5y)156.52%
Cap/Sales(3y)16.64%
Cap/Sales(5y)16.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
EPS Next Y41.77%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.81%
Revenue Next Year3.58%
Revenue Next 2Y7.72%
Revenue Next 3Y11.74%
Revenue Next 5Y21.24%
EBIT growth 1Y27.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.77%
EBIT Next 3Y68.06%
EBIT Next 5Y54.58%
FCF growth 1Y73.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y115.82%
OCF growth 3YN/A
OCF growth 5YN/A